Successful use of ketamine to treat severe depression with suicidality post-COVID-19 - A case report.
Psychiatry Res Case Rep
; 2(1): 100100, 2023 Jun.
Article
in English
| MEDLINE | ID: covidwho-2165776
ABSTRACT
Every second patient who suffers from COVID-19 experiences is at risk for depression. The treatment of severe depression with suicidal risk is challenging in patients with COVID-19 given the restrictions in access to and safety concerns with the use of electroconvulsive therapy during the COVID pandemic. Although ketamine is effective in treating depression, especially in presence of acute suicidality, to date, there are no reports on ketamine use to treat severe depression in the context of COVID-19. In this case report, we describe the success of ketamine to treat a person with severe depression and suicidality following COVID-19 infection.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Case report
/
Prognostic study
/
Qualitative research
Topics:
Long Covid
Language:
English
Journal:
Psychiatry Res Case Rep
Year:
2023
Document Type:
Article
Affiliation country:
J.psycr.2022.100100
Similar
MEDLINE
...
LILACS
LIS